251 Diagnostic utility of molecular and imaging biomarkers 2 Table 59. Baseline characteristics of included studies investigating [99mTc]Tc-MIBI malignant histology, ni reference country study design ntot ni femalei mean agei, y sizei, mm inclusion and exclusion criteria modality main outcome measure PTC FVPTC FTC FTC-OV MTC other n.s. Saggiorato 2009 Italy PS 51 51 78% median 55 10-80 TN ≥10mm; cold on 99mTcO 4 - scintigraphy; Thy3 on FNAC; subsequent thyroid surgery [99mTc]Tc-MIBI; planar dual phase acquisition (early: 10 min; delayed: 120 min) (1) 4-step visual score; (2) lesion to non-lesion early and delayed uptake ratios; retention index (RI) 15 2 2 Giovanella 2015 Switzerland / Italy PS 61 61 72% median 55 (24-81) median 22 (11-50) adults; solitary TN ≥10mm, cold on 99mTcO4 - scintigraphy; suspicious on US; Bethesda IV cytology; normal TSH and calcitonin; subsequent thyroid surgery [99mTc]Tc-MIBI; planar dual phase acquisition (early: 10 min; delayed: 60 min) (1) 3-step visual score; (2) washout index 3 2 5 5 1 Piccardo 2016 Italy PS 87 87 74% 57 24 ±13 TN >1cm; TIR 3; scheduled for surgery; euthyroid; undetectable thyroperoxidase and Tg autoantibodies [99mTc]Tc-MIBI; planar dual phase acquisition (early: 20 min; delayed: 120 min) visual analysis 13 5 TOTAL 199 199 1617125 0 3 0 *: not included in meta-analysis. ntot: total number of thyroid nodules in study. ni: total number of indeterminate thyroid nodules included in our analysis. i: applies to indeterminate thyroid nodules only. PS: prospective. y: years. TN: thyroid nodule. n.s.: not specified. PTC: papillary thyroid carcinoma. FTC-OV: FTC, oncocytic variant (Hürthle cell carcinoma). FVPTC: papillary thyroid carcinoma, follicular variant. FTC: follicular thyroid carcinoma. MTC: medullary thyroid carcinoma.
RkJQdWJsaXNoZXIy MTk4NDMw